The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2025 | TOP-FLOR study: rituximab, golcadomide +/- nivolumab for patients with newly diagnosed FL
Eliza Hawkes, MBBS Hons, FRACP, DMedSc, Olivia Newton-John Cancer Research Institute at Austin Health, Melbourne, Australia, shares insights into the investigator-initiated TOP-FLOR study (NCT05788081), which is evaluating the combination of golcadomide and rituximab +/- nivolumab in patients with treatment-naive follicular lymphoma (FL). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yes, so we’re very excited to be here at ICML releasing some of our first interim analysis results from our investigator-initiated study. This is in treatment-naive follicular lymphoma where we are opting for a chemo-free regimen and we are giving one of the newest agents available to these patients, golcadomide which is a BMS product, along with rituximab as standard of care, then we are randomising patients to this arm or rituximab, golcadomide and nivolumab...
Yes, so we’re very excited to be here at ICML releasing some of our first interim analysis results from our investigator-initiated study. This is in treatment-naive follicular lymphoma where we are opting for a chemo-free regimen and we are giving one of the newest agents available to these patients, golcadomide which is a BMS product, along with rituximab as standard of care, then we are randomising patients to this arm or rituximab, golcadomide and nivolumab. And that is with the strategy that we have an immunomodulatory component to golcadomide and the other CELMoDs and IMiDs, and so we are harnessing that to upregulate the immune system. We’re very excited that the first 11 patients in each arm have been analyzed for efficacy and we have response rates up to 92% in these patients and very manageable toxicity. So we’ll be continuing recruitment and we’re working very closely on some randomized studies with BMS as a follow-on to this so that we can give patients an accessible oral therapy that does not need an inpatient admission or monitoring afterwards for delivery.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
EAH has received research funding Bristol Myers Squibb/Celgene, Merck KgA, AstraZeneca, and F. Hoffmann-La Roche (all paid to institution); has acted as a consultant/advisor for F. Hoffmann-La Roche, Antengene, Bristol Myers Squibb, AstraZeneca, Novartis
